HIV Risk Reduction and Drug Abuse Treatment in Iran

• Status: Withdrawn
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

A randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and HIV risk reduction counseling (DC-HIV) for heroin and opium addicts in Iran.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine; Naltrexone

Criteria

Inclusion Criteria:

• Opioid Dependence

Exclusion Criteria:

• Dependence on alcohol, benzodiazepines or sedatives

• Suicide or homicide risk

• Psychotic disorder or major depression

• Inability to read or understand the protocol or assessment questions

• Life-threatening or unstable medical problems

• Greater than 3 times normal liver enzymes (AST, GGT)